Proactive Investors - Run By Investors For Investors

Aptose Biosciences reaches China distribution deal for CG-806 with South Korea's CrystalGenomics

The pact brings the drug therapy for leukemia to China, Hong Kong and Macau markets
China map
CG-806 is a small molecule that is being developed for the treatment of acute myeloid leukemia

Aptose Biosciences (NASDAQ:APTO) today unveiled a ground-breaking licensing agreement with South Korea’s CrystalGenomics Inc to sell its drug therapy CG-806 in China, Hong Kong and Macau.

CG-806 is a small molecule that is being developed for the treatment of acute myeloid leukemia, B-cell malignancies and additional blood cancers.

Aptose shares climbed 11.8% to US$4.22 in pre-market trade on the back of the company’s deal.

Under the terms, Aptose, which is based in San Diego, California, will pay CrystalGenomics US$3m up front as well as make additional payments for commercial-based milestones and royalties. The deal's value for the China territory, including the upfront payment, could reach as much as US$125mln.

Dr. William Rice, Aptose’s president and chief executive, said pre-clinical work with CG-806 has shown its superior ability to kill B-cell malignancy relative to other treatments.

“We believe that CG-806 has the potential to serve as a transformational agent for multiple hematologic cancers,” he said.

Aptose has been conducting investigational new drug-enabling studies with CG-806 as well as numerous preclinical studies.

View full APS profile View Profile

Aptose Biosciences Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use